Skip to main content

Find Clinical Trials

Home
Conditions
Relapsing Remitting Multiple Sclerosis

Clinical trial condition

Relapsing Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

84 public trials 6 recruiting studies

Refine in advanced search Browse all conditions

Relapsing Remitting Multiple Sclerosis trial results

Completed

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States

View Trial Details

Completed

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

NCT01498887

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Novartis Investigative Site East Gosford, New South Wales, Australia

Novartis Investigative Site Kanwal, New South Wales, Australia

Novartis Investigative Site Liverpool, New South Wales, Australia

Novartis Investigative Site New Lambton Heights, New South Wales, Australia

View all 47 locations

View Trial Details

Completed

Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

NCT01307332

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Brain Diseases, +9 more
Locations: University of British Columbia Hospital Vancouver, British Columbia, Canada

View Trial Details

Completed

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

NCT01185821

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Novartis Investigative Site Miami, Florida, United States

Novartis Investigative Site Pompano Beach, Florida, United States

Novartis Investigative Site Tallahassee, Florida, United States

Novartis Investigative Site Chicago, Illinois, United States

View all 46 locations

View Trial Details

Completed

Atorvastatin in Relapsing-Remitting Multiple Sclerosis

NCT00616187

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Not specified

View Trial Details

Completed

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

NCT00837785

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Research Site Berlin, Germany

View Trial Details

Completed

A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis

NCT02647502

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Johns Hopkins University Baltimore, Maryland, United States

View Trial Details

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis

NCT01767701

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: The Royal London Hospital London, United Kingdom

View Trial Details

Completed

Safety of New Formulation of Glatiramer Acetate

NCT00947752

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Not specified

View Trial Details

Completed

Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.

NCT01808885

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Timone University Hospital, Neurology Department, UMR CRMBM CNRS 6612 Marseille, France

CHU Reims, Maison Blanche Hospital, Neurology Department & University of Reims Reims, France

CHU Pontchaillou, Neurology Department Rennes, France

View Trial Details